Inclusion of CYP3A5 genotyping in a nonparametric population model improves dosing of tacrolimus early after transplantation

Transplant International

Volumn 26, Issue 12, 2013, Pages 1198-1207

  Åsberg, Anders ^a,b   Midtvedt, Karsten ^b   Van Guilder, Mike ^c   Størset, Elisabet ^b   Bremer, Sara ^b   Bergan, Stein ^a,b   Jelliffe, Roger ^c   Hartmann, Anders ^b   Neely, Michael N ^c  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

CYP3A5; dosing; nonparametric; population pharmacokinetics; tacrolimus

Indexed keywords

BASILIXIMAB; CYTOCHROME P450 3A5; HUMAN IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; STEROID; TACROLIMUS;

ARTICLE; BODY MASS; BODY SIZE; COMPARTMENT MODEL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MEGADOSE; DRUG MONITORING; FAT FREE MASS; GENOTYPE; GRAFT RECIPIENT; HEMATOCRIT; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LAG; MAJOR CLINICAL STUDY; NONPARAMETRIC TEST; POPULATION MODEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; TIME;

CYP3A5; DOSING; NONPARAMETRIC; POPULATION PHARMACOKINETICS; TACROLIMUS;

ADULT; BIOLOGICAL AVAILABILITY; CYTOCHROME P-450 CYP3A; FEMALE; GENOTYPE; HUMANS; KIDNEY TRANSPLANTATION; MALE; MODELS, BIOLOGICAL; STATISTICS, NONPARAMETRIC; TACROLIMUS;

EID: 84888055282     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12194     Document Type: Article

References (44)

1. Dai Y, Hebert MF, Isoherranen N, et al,. Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab Dispos 2006; 34: 836.
2. Kamdem LK, Streit F, Zanger UM, et al,. Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin Chem 2005; 51: 1374.
3. Nagase K, Iwasaki K, Nozaki K, Noda K,. Distribution and protein binding of FK506, a potent immunosuppressive macrolide lactone, in human blood and its uptake by erythrocytes. J Pharm Pharmacol 1994; 46: 113.
4. Staatz CE, Tett SE,. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 2004; 43: 623.
5. Elens L, van Schaik RH, Panin N, et al,. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenomics 2011; 12: 1383.
6. House AA, Elmestiri M, Denesyk K, et al,. Apparent low absorbers of cyclosporine microemulsion have higher requirements for tacrolimus in renal transplantation. Clin Transplant 2007; 21: 518.
7. Mourad M, Wallemacq P, De Meyer M, et al,. The influence of genetic polymorphisms of cytochrome P450 3A5 and ABCB1 on starting dose- and weight-standardized tacrolimus trough concentrations after kidney transplantation in relation to renal function. Clin Chem Lab Med 2006; 44: 1192.
8. Passey C, Birnbaum AK, Brundage RC, Oetting WS, Israni AK, Jacobson PA,. Dosing equation for tacrolimus using genetic variants and clinical factors. Br J Clin Pharmacol 2011; 72: 948.
9. Press RR, Ploeger BA, den Hartigh J, et al,. Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. Ther Drug Monit 2009; 31: 187.
10. Antignac M, Barrou B, Farinotti R, Lechat P, Urien S,. Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients. Br J Clin Pharmacol 2007; 64: 750.
11. Benkali K, Premaud A, Picard N, et al,. Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients. Clin Pharmacokinet 2009; 48: 805.
12. Han N, Yun HY, Hong JY, et al,. Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients. Eur J Clin Pharmacol 2013; 69: 53.
13. Musuamba FT, Mourad M, Haufroid V, Delattre IK, Verbeeck RK, Wallemacq P,. Time of drug administration, CYP3A5 and ABCB1 genotypes, and analytical method influence tacrolimus pharmacokinetics: a population pharmacokinetic study. Ther Drug Monit 2009; 31: 734.
14. Musuamba FT, Mourad M, Haufroid V, et al,. A simultaneous d-optimal designed study for population pharmacokinetic analyses of mycophenolic Acid and tacrolimus early after renal transplantation. J Clin Pharmacol 2012; 52: 1833.
15. Staatz CE, Willis C, Taylor PJ, Tett SE,. Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. Clin Pharmacol Ther 2002; 72: 660.
16. Velickovic-Radovanovic R, Catic-Djordjevic A, Milovanovic JR, Djordjevic V, Paunovic G, Jankovic SM,. Population pharmacokinetics of tacrolimus in kidney transplant patients. Int J Clin Pharmacol Ther 2010; 48: 375.
17. Woillard JB, de Winter BC, Kamar N, Marquet P, Rostaing L, Rousseau A,. Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations-twice daily Prograf and once daily Advagraf. Br J Clin Pharmacol 2011; 71: 391.
18. Zuo XC, Ng CM, Barrett JS, et al,. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis. Pharmacogenet Genomics 2013; 23: 251.
19. Neely MN, van Guilder MG, Yamada WM, Schumitzky A, Jelliffe RW,. Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R. Ther Drug Monit 2012; 34: 467.
20. Falck P, Vethe NT, Åsberg A, et al,. Cinacalcet's effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients. Nephrol Dial Transplant 2008; 23: 1048.
21. Midtvedt K, Jenssen T, Hartmann A, et al,. No change in insulin sensitivity in renal transplant recipients converted from standard to once-daily prolonged release tacrolimus. Nephrol Dial Transplant 2011; 26: 3767.
22. Størset E, Holford N, Midtvedt K, Bremer S, Bergan S, Åsberg A,. Importance of hematocrit for a tacrolimus target concentration strategy. Eur J Clin Pharmacol 2013. [Epub ahead of print].
23. Amundsen R, Asberg A, Robertsen I, et al,. Rimonabant affects cyclosporine a, but not tacrolimus pharmacokinetics in renal transplant recipients. Transplantation 2009; 87: 1221.
24. Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B,. Quantification of lean bodyweight. Clin Pharmacokinet 2005; 44: 1051.
25. Seifeldin RA, Marcos-Alvarez A, Gordon FD, Lewis WD, Jenkins RL,. Nifedipine interaction with tacrolimus in liver transplant recipients. Ann Pharmacother 1997; 31: 571.
26. Lemahieu W, Maes B, Verbeke K, Rutgeerts P, Geboes K, Vanrenterghem Y,. Cytochrome P450 3A4 and P-glycoprotein activity and assimilation of tacrolimus in transplant patients with persistent diarrhea. Am J Transplant 2005; 5: 1383.
27. Katz DA, Grimm DR, Cassar SC, et al,. CYP3A5 genotype has a dose-dependent effect on ABT-773 plasma levels. Clin Pharmacol Ther 2004; 75: 516.
28. Anderson BJ, Holford NH,. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet 2009; 24: 25.
29. Ludden TM, Beal SL, Sheiner LB,. Comparison of the Akaike Information Criterion, the Schwarz criterion and the F test as guides to model selection. J Pharmacokinet Biopharm 1994; 22: 431.
30. Benkali K, Rostaing L, Premaud A, et al,. Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation. Clin Pharmacokinet 2010; 49: 683.
31. Li D, Lu W, Zhu JY, Gao J, Lou YQ, Zhang GL,. Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patients. J Clin Pharm Ther 2007; 32: 505.
32. Monchaud C, de Winter BC, Knoop C, et al,. Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation. Clin Pharmacokinet 2012; 51: 175.
33. Shi XJ, Geng F, Jiao Z, Cui XY, Qiu XY, Zhong MK,. Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis. J Clin Pharm Ther 2011; 36: 614.
34. de Jonge H, de Loor H, Verbeke K, Vanrenterghem Y, Kuypers DR,. In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients. Clin Pharmacol Ther 2012; 92: 366.
35. MacPhee IA, Fredericks S, Tai T, et al,. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am J Transplant 2004; 4: 914.
36. Hesselink DA, van Schaik RH, van Agteren M, et al,. CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients. Pharmacogenet Genomics 2008; 18: 339.
37. Thervet E, Loriot MA, Barbier S, et al,. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther 2010; 87: 721.
38. Barraclough KA, Staatz CE, Johnson DW, et al,. Kidney transplant outcomes are related to tacrolimus, mycophenolic acid and prednisolone exposure in the first week. Transpl Int 2012; 25: 1182.
39. Kuypers DR, de Jonge H, Naesens M, Vanrenterghem Y,. A prospective, open-label, observational clinical cohort study of the association between delayed renal allograft function, tacrolimus exposure, and CYP3A5 genotype in adult recipients. Clin Ther 2010; 32: 2012.
40. Ogasawara K, Chitnis SD, Gohh RY, Christians U, Akhlaghi F,. Multidrug Resistance-Associated Protein 2 (MRP2/ABCC2) Haplotypes Significantly Affect the Pharmacokinetics of Tacrolimus in Kidney Transplant Recipients. Clin Pharmacokinet 2013; 52: 751.
41. Ekberg H, Tedesco-Silva H, Demirbas A, et al,. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562.
42. Andres A, Budde K, Clavien PA, et al,. A randomized trial comparing renal function in older kidney transplant patients following delayed versus immediate tacrolimus administration. Transplantation 2009; 88: 1101.
43. Osuna A, Gentil MA, Capdevila L, et al,. Two doses of daclizumab with delayed introduction of low-dose tacrolimus in elderly recipients of cadaveric renal transplants from donors >55 years of age. Transplant Proc 2005; 37: 1438.
44. Neuberger JM, Mamelok RD, Neuhaus P, et al,. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study. Am J Transplant 2009; 9: 327.